High Flow Hacks, Part 2

High-flow nasal cannula is a humidified, high-flow oxygen strategy for acute hypoxemic respiratory failure, not a replacement for BiPAP in hypercapnic COPD or cardiogenic pulmonary edema. The key bedside question is who will improve on HFNC and who is declaring early failure.

High-Flow Nasal Cannula Basics

• Best-fit clinical phenotype: HFNC fits acute hypoxemic respiratory failure, especially when patients need high FiO2 but would benefit from a nasal interface they can tolerate while talking, eating, or clearing secretions.
• Physiology of high flow: Flow does more than deliver oxygen: heated humidification improves comfort, high rates wash out dead space, and a closed mouth can generate a modest PEEP effect of about 1 cm H2O per 10 L/min.
• Initial bedside targets: Set FiO2 to an SpO2 of 92-96%, use 37 C for humidification, and titrate flow to visible work of breathing rather than treating the liters per minute as a fixed number.
• Situations favoring HFNC: HFNC is particularly useful for sepsis, secretion-heavy patients, mask intolerance, and preoxygenation before intubation. We get into the setup nuances in the episode.
• When HFNC is wrong tool: HFNC does not provide the inspiratory pressure support that mechanical respiratory failure needs, so COPD exacerbations and CHF remain classic BiPAP territory with known mortality benefit.

Recognizing HFNC Failure Early

• ROX index trend: The ROX index combines oxygenation with respiratory rate and is the most practical ED tool for tracking HFNC success versus looming intubation, with serial checkpoints that matter. We walk through the timing nuances in the episode.
• Worsening oxygenation markers: A falling P/F ratio signals worsening lung injury, but it is less ED-friendly because it usually requires repeated ABGs and trend data over hours rather than a quick bedside reassessment.
• Severity score context: Rising SOFA or APACHE scores correlate with HFNC failure, but they are cumbersome for real-time emergency care and should not distract from the patient's trajectory at the bedside.
• Escalation ceiling awareness: Maxing out HFNC should trigger parallel planning for intubation, because delayed recognition of failure can worsen outcomes in acute hypoxemic respiratory failure.
• Noninvasive step after HFNC: Switching from HFNC to BiPAP is usually not the next best move unless the original diagnosis was wrong and the patient actually has a pressure-support problem such as COPD or CHF.

BiPAP, CPAP, and Intubation Thresholds

• CPAP versus BiPAP distinction: CPAP is continuous positive pressure, while BiPAP adds inspiratory support akin to pressure support ventilation, making it the more common ED choice when work of breathing is high.
• Mortality-benefit indications: BiPAP remains the evidence-based first-line noninvasive strategy for COPD and acute CHF, where inspiratory assistance and positive pressure improve more than oxygenation alone.
• Tolerance without oversedation: Start with verbal de-escalation, avoid benzodiazepines, and if needed use small-dose ketamine or fentanyl cautiously because preserving respiratory drive and hemodynamics is the whole game.
• Hemodynamic PEEP caution: PEEP recruits alveoli and improves VQ matching, but it can also reduce preload in a dose-dependent way, a key hazard when initiating positive pressure in cardiogenic shock.
• Signals to intubate now: Worsening hypoxia, rising work of breathing, aspiration risk, falling mental status, or arrest are hard stops for noninvasive support. That bedside pivot is worth hearing in the chapter.

References:

1. Roca O, et al. An Index Combining Respiratory Rate and Oxygenation to Predict Outcome of Nasal High-Flow Therapy. Am J Respir Crit Care Med. 2019;199(11):1368-1376. PMID: 30576221
2. Rochwerg B, et al. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis. Intensive Care Med. 2019;45(5):563-572. PMID: 30888444
3. Ou X,et al. Effect of high-flow nasal cannula oxygen therapy in adults with acute hypoxemic respiratory failure: a meta-analysis of randomized controlled trials. CMAJ. 2017;189(7):E260-E267. PMID: 28246239
4. Ferreyro BL, et al. Association of Noninvasive Oxygenation Strategies With All-Cause Mortality in Adults With Acute Hypoxemic Respiratory Failure: A Systematic Review and Meta-analysis. JAMA. 2020;324(1):57-67. PMID: 32496521
5. Li J,et al. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Eur Respir J. 2020;55(5):2000892. Published 2020 May 14. PMID: 32299867
6. Mauri T, et al. Physiologic Effects of High-Flow Nasal Cannula in Acute Hypoxemic Respiratory Failure. Am J Respir Crit Care Med. 2017;195(9):1207-1215. PMID: 27997805
7. Kang BJ, et al. Failure of high-flow nasal cannula therapy may delay intubation and increase mortality. Intensive Care Med. 2015;41(4):623-632. PMID: 25691263
8. Mauri T, et al. Optimum support by high-flow nasal cannula in acute hypoxemic respiratory failure: effects of increasing flow rates. Intensive Care Med. 2017;43(10):1453-1463. PMID: 28762180
9. Kim SH, Kim CH, Kim SY, Song SH et al. Predicting factors for the failure of high flow nasal cannula therapy in patients with acute respiratory failure. European Resp Journal 2018;PA2297. DOI: 10.1183/13993003.congress-2018.PA2297